Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation May 28, 2025 May 28, 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025 May 7, 2025 May 7, 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI March 31, 2025 March 31, 2025
FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder February 25, 2025 February 25, 2025
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia February 10, 2025 February 10, 2025
